SCHEMBL7234553

SCHEMBL7234553

CCN1C(=O)C(C(=O)O)c2cc(C3(C)OCCO3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
TSHR P16473 3/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
USP2 O75604 1/20 0.38
MEN1 O00255 7/20 0.33
KMT2A Q03164 7/20 0.33
HKDC1 Q2TB90 7/20 0.33
CASP6 P55212 3/20 0.33
POLB P06746 2/20 0.33
CFTR P13569 3/20 0.32
GOPC Q9HD26 3/20 0.32
UBE2I P63279 3/20 0.32
SAE1 Q9UBE0 3/20 0.32
UBA2 Q9UBT2 3/20 0.32
LMNA P02545 3/20 0.32
TDP2 O95551 2/20 0.32
HTT P42858 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9667266 0.91 ALDH1A1 (0.40) ALDH1A1TSHRKDM4EGAAMEN1
SCHEMBL7236836 0.88 USP2 (0.43) ALDH1A1TSHRKDM4EGAAUSP2
SCHEMBL9666424 0.84 CYP19A1 (0.35) ALDH1A1TSHR
SCHEMBL9666166 0.80 L3MBTL1 (0.43) MEN1KMT2AHKDC1CASP6POLB
SCHEMBL10747205 0.78 ALDH1A1 (0.40) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL7234484 0.76 ALDH1A1 (0.45) ALDH1A1TSHRKDM4EGAAUSP2
SCHEMBL9665384 0.74 TDP2 (0.37) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL10741283 0.74 TDP2 (0.35) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL7237207 0.73 MEN1 (0.38) ALDH1A1GAAMEN1KMT2AHKDC1
SCHEMBL7242408 0.71 ALDH1A1 (0.43) ALDH1A1TSHRKDM4EGAAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030004162-A1 Use of glycogen phosphorylase inhibitors TREADWAY JUDITH L (US) 2003-01-02 US disclosed
US-20020031816-A1 METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE PFIZER PRODUCTS INC. 2002-03-14 US disclosed
EP-1136071-A2 Use of glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-09-26 EP disclosed
EP-0978279-A1 Inhibitors of human glycogen phosphorylase Pfizer Products Inc. (US) 2000-02-09 EP disclosed
US-5998463-A Glycogen phosphorylase inhibitors PFIZER INC (US) 1999-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004162-A1 Use of glycogen phosphorylase inhibitors PYGL, PYGM, GYS2 ALDH1A1 2056/4885TSHR 4593/4885KDM4E 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.